Lotte Biologics

As a global leading CDMO, Lotte Biologics is committed to improving the lives of patients worldwide. LOTTE BIOLOGICS was established in 2022 and is headquartered in Seoul, South Korea. LOTTE BIOLOGICS has strengthened its competitiveness in the CDMO market through a dual-track strategy of acquisitions and establishment. Currently, the company owns a biopharmaceutical antibody production campus in the Syracuse area of the United States and is constructing a 360,000-liter bio-campus in Songdo, Incheon, South Korea.